FDA 483 - Vetter Pharma Fertigung GmbH & Co. KG - April 24, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Vetter Pharma-Fertigung GmbH & Co. KG in Langenargen, Germany, a sterile drug product manufacturer, revealed significant deficiencies. Observations included failures to prevent microbiological contamination during aseptic filling, an inadequate visual inspection program that repeatedly failed to remove defective products, and deficient environmental monitoring in aseptic processing areas. These issues raise concerns about the sterility assurance and quality control of their sterile drug products.
ID · f7bee0de-fc90-415f-b6d8-541427e248c0